Transfusion-associated GVHD: 10 years' experience at the American University of Beirut-Medical Center.

TitleTransfusion-associated GVHD: 10 years' experience at the American University of Beirut-Medical Center.
Publication TypeJournal Article
Year of Publication2003
AuthorsAoun E, Shamseddine A, Chehal A, Obeid M, Taher A
Pagination1672 - 6
Date Published2003
ISBN Number0041-1132
Other Numberswdn, 0417360
Keywords*Blood Transfusion/ae [Adverse Effects], *Graft vs Host Disease/et [Etiology], *Graft vs Host Disease/mo [Mortality], Adult, Aged, Antilymphocyte Serum/tu [Therapeutic Use], Cyclosporine/tu [Therapeutic Use], Female, Graft vs Host Disease/di [Diagnosis], Graft vs Host Disease/dt [Drug Therapy], Granulocyte Colony-Stimulating Factor/tu [Therapeutic Use], Humans, Immunosuppressive Agents/tu [Therapeutic Use], Infant, Male, Medical Records, Middle Aged, Muromonab-CD3/tu [Therapeutic Use], Steroids/tu [Therapeutic Use]

BACKGROUND: Although rare, transfusion-associated GVHD (TA-GVHD) is a fatal complication of blood transfusion in which active lymphocytes from the donor attack and destroy recipient organs and tissues., STUDY DESIGN AND METHODS: A search of patient records was carried out at the American University of Beirut-Medical Center, looking for patients who developed TA-GVHD over a 10-year period extending from 1991 to 2001. Relevant information was collected and analyzed., RESULTS: A total of 10 records were found as a result of this search. All were immunocompetent and received fresh nonleukoreduced, nonirradiated blood. The majority received the transfusion at outside periphery hospitals. They received different treatment modalities. The mortality rate was 100 percent., CONCLUSION: TA-GVHD is a serious complication with very high mortality. Effective prevention guidelines should be established in Lebanon including irradiation and the creation of a central blood bank.

Notify Library Reference ID4215

Related Incidents